METABOLIC
RETATRUTIDE (GLP-3)
10MG
Retatrutide is a next-generation triple-receptor agonist designed to engage the body’s GLP-1, GIP, and glucagon pathways - key regulators of metabolic function, appetite signaling, and glucose balance. By targeting these complementary systems it can support comprehensive metabolic optimization. Dosing is initiated conservatively and can be increased over time through a stepwise approach based on individual goals, response, and overall tolerance, allowing for a personalized protocol aligned with participant’s unique physiology.
SELECT DOSE:
Regular Price: $119.99
$134.99
FREE Shipping on orders over $200
MOLECULAR FORMULA
C312H479N87O95
Quantity Discounts Available
Product Usage: For Research Use Only – Not for Human or Veterinary Use
This product is not a drug, food, cosmetic, or dietary supplement and has not been evaluated by the FDA. It is strictly intended for in vitro research by qualified professionals. Any use in humans or animals is strictly prohibited and may violate federal, state, or local laws, including the Federal Food, Drug, and Cosmetic Act. No therapeutic or diagnostic application is implied or permitted. The purchaser assumes all responsibility for compliance with applicable regulations.
Retatrutide (GLP-3) Research Peptide
Retatrutide is a next-generation triple-receptor agonist designed to engage the body’s GLP-1, GIP, and glucagon pathways - key regulators of metabolic function, appetite signaling, and glucose balance. By targeting these complementary systems it can support comprehensive metabolic optimization. Dosing is initiated conservatively and can be increased over time through a stepwise approach based on individual goals, response, and overall tolerance, allowing for a personalized protocol aligned with participant’s unique physiology.
Chemical Info
CAS Number
2381089-83-2
PubChem CID
171390338
Molecular Weight
4731.33 g/mol
Molecular Formula
C221H342N46O68
Synonyms
Triple GLP-1, GLP3, RETA, LY3437943
Purity
≥ 99% HPLC
Storage
Store in lyophilized form at -20°C to maintain compound stability.
Store protected from direct light exposure to reduce degradation.
Keep totally dry and avoid moisture exposure prior to reconstitution.
Keep vial tightly sealed when not in use to preserve integrity.
Triple-Pathway Metabolic Regulation
RETA is a primary focus for investigating the synergistic activation of the metabolic triad: GLP-1, GIP, and Glucagon receptors. Researchers utilize this model to monitor how triple-agonism affects insulin secretion, fatty acid metabolism, and energy expenditure. This research aims to quantify the total metabolic shift when all three pathways are engaged compared to single or dual-agonist models.
Thermogenesis and Resting Metabolic Rate
A key component of RETA research is the inclusion of glucagon receptor agonism. Research suggests that targeting this receptor increases the metabolic rate by promoting lipolysis and hepatic energy expenditure. Researchers monitor these effects to determine the impact on resting energy expenditure and the potential for mitigating metabolic slowing during prolonged caloric restriction in animal subjects.
Glucose Homeostasis and Insulin Sensitivity
Beyond energy expenditure, RETA is utilized to observe changes in systemic glucose control. Studies track the activation of secondary messengers in the liver and pancreas to evaluate the sensitivity of the hormonal response to triple signaling. This research explores how localized signaling from these three receptors can stabilize blood glucose levels and restore endocrine balance in specialized metabolic research models.